23andMe Wants FDA Approval for Personal DNA Testing. What Can It Reveal?
By Bonnie Rochman,
TIME Healthland
| 08. 02. 2012
Earlier this week, the personal gene-testing company 23andMe announced that
it’s seeking the blessing of the Food and Drug Administration (FDA) for
its DNA tests that allow people to peer into their genetic makeup.
If the FDA grants approval, it would be a major step forward for the
growing industry springing up around genetic testing. Every day, it
seems, scientists are reporting new gene-based discoveries that allow
them to better pinpoint the causes of disease. As technology becomes
increasingly sophisticated, single-gene tests are being joined by the
sort of genotyping technology used by 23andMe, which scans about 1
million points on the genome that are known to vary among humans. An
even more complex technique, genomic sequencing, looks at about 3
billion points that cover a person’s entire genetic code. 23andMe — the
name is a reference to the 23 pairs of chromosomes that comprise a
person’s genome — intends to eventually offer sequencing, but the cost
starts at around $4,000, which is considerably more expensive than the
$299 the company charges for its testing.
Not only is sequencing more...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...